Research Article

Probiotics Fermentation Technology, a Novel Kefir Product, Ameliorates Cognitive Impairment in Streptozotocin-Induced Sporadic Alzheimer’s Disease in Mice

Nesrine S. El Sayed 1, Esraa A. Kandil 1, and Mamdooh H. Ghoneum 2

1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt
2Department of Surgery, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA

Correspondence should be addressed to Nesrine S. El Sayed; nesrine_salah2002@yahoo.com

Received 1 February 2021; Revised 28 March 2021; Accepted 4 June 2021; Published 8 July 2021

Copyright © 2021 Nesrine S. El Sayed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by cognitive impairment. Gut microbiota dysfunction (dysbiosis) is implicated in the pathology of AD and is associated with several detrimental consequences, including neurotransmitter depletion, oxidative stress, inflammation, apoptosis, and insulin resistance, which all contribute to the onset of AD. The objective of this study was to assess the effectiveness of Probiotics Fermentation Technology (PFT), a kefir product, in alleviating AD symptoms via regulation of the gut microbiota using a streptozotocin- (STZ-) induced AD mouse model and to compare its activity with simvastatin, which has been proven to effectively treat AD. Mice received one intracerebroventricular injection of STZ (3 mg/kg). PFT (100, 300, 600 mg/kg) and simvastatin (20 mg/kg) were administered orally for 3 weeks. PFT supplementation mitigated STZ-induced neuronal degeneration in the cortex and hippocampus, restored hippocampal acetylcholine levels, and improved cognition in a dose-dependent manner. These effects were accompanied by reductions in oxidative damage, proinflammatory cytokine expression, apoptosis, and tau hyperphosphorylation. Moreover, PFT hindered amyloid plaque accumulation via the enhancement of insulin-degrading enzyme. These beneficial effects were comparable to those produced by simvastatin. The results suggest that PFT can alleviate AD symptoms by regulating the gut microbiota and by inhibiting AD-related pathological events.

1. Introduction

Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder [1]. It is a devastating disease that is characterized by progressive cognitive impairment and memory loss [2]. The fundamental pathological hallmarks of AD are amyloid plaques (extracellular accumulations of abnormally folded amyloid beta protein (Aβ)) and neurofibrillary tangles that are composed of hyperphosphorylated tau protein [3]. The pathophysiological aspects of AD have not yet been fully investigated; however, synaptic dysfunction, membrane permeabilization, oxidative stress, inflammation, apoptosis, and a reduction in cerebral glucose utilization have been identified as risk factors of AD progression [4, 5]. Interestingly, it has recently been proposed that gut microbiota dysfunction (dysbiosis) correlates with the onset of AD [6, 7]. This hypothesis is based on many lines of evidence. First, the gut microbiota composition is influenced by aging, the main risk factor for AD [8]. Second, alterations in the microbiota lead to the release of significant quantities of amyloids and lipopolysaccharides, which modulate signaling pathways, increase the permeability of the intestine and the blood-brain barrier, and produce proinflammatory cytokines, which are all related to AD pathogenesis [7, 9, 10]. Third, dysbiosis generates oxidative stress, which is also associated with AD [11]. Furthermore, disturbance of the gut microbiome confers insulin resistance, which has also been linked with AD [8]. Therefore, AD is intrinsically interrelated with gut microbiota imbalance and may initiate from the gut. To this end, the modulation of
the gut microbiota has become of increasing interest in the quest for new AD therapeutic agents.

Probiotic fermentation technology (PFT), a kefir grain product, is extracted from kefir (fermented milk) [12, 13]. Kefir is a health-endorsing probiotic drink that is formed by the fermentation of milk with kefir grains and is composed of mainly Lactobacillus kefir. Earlier studies have demonstrated the numerous health benefits of kefir-derived Lactobacillus kefir: it improves gut health by preserving the probiotic bacteria balance and reduces oxidative stress, inflammation, and insulin resistance [12, 14–17]. Interestingly, PFT has recently been examined for its ability to exert anticancer effects in animals with Ehrlich ascites carcinoma and in human gastric cancer cells in vitro [18, 19]. Since the majority of AD patients are elderly, the development of safe, well-tolerated drugs is important. Our recent study showed the effectiveness of PFT supplementation in modulating age-associated oxidative stress, suggesting that PFT may be a valuable therapeutic intervention for AD [20]. In addition, PFT has been shown to be a safe, nontoxic agent with no side effects [18].

In this study, we explore the potential effects of PFT in the treatment of AD, as well as comparing its activity with simvastatin, which has been proven to treat dementia, reduce cognitive decline in AD patients, and diminish the prevalence of AD [21, 22].

2. Materials and Methods

2.1. Animals. Adult male albino mice (25–30 g) were obtained from the animal facility of the Faculty of Pharmacy, Cairo University, Egypt. Mice were housed at a constant temperature (25°C ± 2°C) and humidity level (60% ± 10%) under a 12/12 h light/dark cycle and were allowed a standard chow diet and water ad libitum. The study was approved by the Institutional Animal Care and Use Committee of Cairo University (CU-IACUC) (Permit Number: CU-III-F-35-20) and complied with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 2011).

2.2. Chemicals and Drugs. PFT kefir grain product is a mixture that primarily (~90%) consists of a heat-killed freeze-dried form of L. kefir P-IF, whose characteristics have been reported previously [12, 13]. PFT also contains ~2%–3% of the following: one bacterial strain (L. kefir P-B1) and the yeast strains Kazachstania turicensis, Kazachstania unispora, and Kluyveromyces marxianus. Positron-emission tomography scans showed 99.6% homology with regular kefirs. The yeast strains are not intentionally added but are present in large amounts when the product is obtained from the Caucasus mountains and are filtered out in order to maximize the Lactobacillus kefir levels. PFT was provided by Paitos Co. Ltd. (Yokohama, Kanagawa, Japan).

Streptozotocin (STZ) and simvastatin were purchased from Sigma–Aldrich (St. Louis, MO, USA). Other chemicals and reagents, unless otherwise specified, were obtained from Sigma–Aldrich Chemical Co. (St. Louis, MO, USA).

2.3. Induction of AD. Intracerebroventricular (ICV) injection of STZ, first described by Pelleymounter et al. and modified by Warnock, was used in the current study for the avoidance of cerebral vein penetration [23–25]. Mice were anesthetized with thiopental with 5 mg/kg, i.p., then the mouse’s head was stabilized using downward pressure above the ears, and the needle was inserted directly through the skin and skull into the lateral ventricle, which was targeted by visualizing an equilateral triangle between the eyes and the center of the skull to locate the bregma, allowing the needle to be inserted at the following coordinates from the bregma: 1 mm medio-lateral, –0.1 mm anteroposterior, and 3 mm dorsoventral. Mice behaved normally approximately 1 min following the injection. The accuracy of the injection technique was established by injecting methylene blue dye that was detected in the lateral ventricles [26].

2.4. Experimental Design. Mice were randomly allocated into six groups, with 12 mice in each group. The study was conducted for a total of 21 days. Group I, the sham control group, received one ICV injection of 0.9% saline, in addition to oral administration of Tween 80 with 0.9% saline, daily for 21 consecutive days. Group II, the AD-model group, received one ICV injection of STZ (3 mg/kg) dissolved in 0.9% saline [27]. Groups III to VI received one ICV STZ injection (3 mg/kg), and group III was treated with simvastatin (20 mg/kg, p.o.) suspended in Tween 80 with 0.9% saline 5 h after STZ injection and then daily for a total of 21 doses [28]. Groups IV to VI were treated with PFT (100 mg, 300 mg, and 600 mg/kg, p.o., respectively) suspended in Tween 80 with 0.9% saline 5 h after STZ injection and then daily for a total of 21 doses (Figure 1) [29].

2.5. Behavioral Assessment. Twenty-four hours after the last drug doses, behavioral tests were conducted. These tests were arranged sequentially from least stressful to most stressful and were carried out during the light cycle under top lighting in order to lessen potential circadian variability.

2.5.1. Novel Object Recognition Test. The novel object recognition (NOR) test, used to assess learning and memory, is based on the innate preference for novelty that mice exhibit, where mice that remember the familiar object will take more time exploring a novel object. This test was accomplished by following the procedure described by Antunes and Biala [30]. The test took place over three consecutive days: habituation day, training day, and test day (days 20, 21, and 22, respectively). On habituation day, mice were placed individually into a wooden box (40 cm × 40 cm × 40 cm) and were allowed to explore the environment (without objects) for 10 min. On training day, mice were placed individually in the middle of the box and given 10 min to visually explore two identical objects placed along the diagonal of the box (one in the northwest corner and one in the southeast corner). On testing day, one of the previously explored objects was replaced by a novel object (the diagonal used on the training day was the same as that used on the testing day), and each mouse was given 3 min to explore the objects in the box. Objects that are simply discriminated by mice with
the presence of protrusions/intrusions on the surface and have a comparable degree of complexity (texture, shape, color patterning, and brightness, etc.) were selected in order to diminish bias due to object preference [31]. Moreover, objects that are mouse-sized or only slightly larger to encourage exploration were used, and they were made of nonbreakable material, to avoid object damage during experimentation and hence interfere with the continuing testing and to avoid animals’ injury. Great attention was directed to the object odors; thus, multiple copies of the sample objects were available and each copy was used only for the same animal and all objects were cleaned with 70% ethanol after each test to eliminate possible bias due to odors left by previous animals [32]. Exploration was defined as directing the nose to the object at a distance of less than 2 cm, while sitting on the object was not considered exploration. The animals’ behavior was video recorded, and the following parameters were calculated:

(1) Discrimination Index. Difference in time exploring the novel and familiar objects divided by the total time spent exploring both objects (this value varies between −1 and +1, with a negative score indicating that the mouse spends more time exploring the familiar object, a zero-score indicating that the mouse has no preference, and a positive score indicating that the mouse spends more time exploring the novel object).

(2) Recognition Index. Time spent by the animal exploring the novel object as a percentage of the total exploration time.

2.5.2. Morris Water Maze Test. The Morris water maze (MWM) test, used to investigate spatial memory and learning, was performed as described by D’Hooge and De Deyn [33]. A stainless-steel circular tank (150 cm in diameter and 60 cm in height) was filled with water (25°C ± 2°C) to a depth of 35 cm and divided into four quadrants. A black platform (10 cm width, 28 cm height) was positioned inside the target quadrant, and the tank was filled to 2 cm below the top of the platform. The platform was maintained in the same location during the training and testing procedures. During testing, the platform was made invisible to the mice by making the water opaque with a purple-colored nontoxic tempera paint. It is important to ensure that animals can swim adequately before performing the training and testing procedures [34]. This was accomplished by allowing each mouse to swim in the pool to reach a platform that is maintained above the water level. The animal that can swim directly to the visible platform without difficulty was used to perform training and testing procedures. Memory acquisition trials (120 s/trial) were performed over four consecutive days (days 18, 19, 20, and 21), twice a day, with at least 15 min between trials. During training, animals were left to locate the hidden platform in the target quadrant. If the mouse found the hidden platform within 120 s, it was kept there for an additional 20 s before being removed, while if it failed to find the hidden platform during the designated time, the mouse was gently guided to the platform and kept there for 20 s. The mean escape latency was calculated as the time taken by each mouse to find the hidden platform and was used as an index of acquisition or learning. On the fifth day (day 22), mice underwent a probe trial session, in which the platform was removed, and each mouse was given 60 s to explore the pool. The time each mouse spent in the target quadrant in which the hidden platform was previously placed was determined and used as an indicator of retrieval or memory.

2.6. Brain Processing. After evaluation of cognitive performance, the mice in each group were divided into three sets and were euthanized by cervical dislocation under light anesthesia. Subsequently, the brains were rapidly dissected and washed with ice-cold saline. In the first set (n = 3 per group), brains were fixed in 10% (v/v) formalin for 24 h to perform histopathological staining with hematoxylin and eosin (HE), Congo red, and Nissl stain. In the other sets, the hippocampal tissues were excised from each brain on an ice-cold glass plate. In the second set (n = 6 per group), the hippocampi were homogenized in ice-cold physiological saline (10% w/v), then the hippocampal homogenates were used for determination of the levels of acetylcholine (Ach), amyloid β_{42}, oxidative stress parameters (malondialdehyde, MDA; nuclear factor erythroid 2-related factor 2, Nrf-2; heme oxygenase-1, HO-1; and glutathione, GSH), inflammatory markers (nuclear factor kappa beta, NF-κB; NLRP3;
interleukin 1β, IL-1β; and tumor necrosis factor-alpha, TNF-α), caspase-3, and insulin-degrading enzyme (IDE). In the third set (n = 3 per group), hippocampi were used for the assessment of protein expression of phosphorylated tau, glycogen synthase kinase 3β (GSK-3β), and mammalian target of rapamycin (mTOR), as well as the determination of extracellular signal-regulated protein kinase (ERK1/2) and p38 mitogen-activated protein kinase (p38-MAPK) gene expression.

2.7. Measured Parameters

2.7.1. Enzyme-Linked Immunosorbent Assay of Levels of Ach, Amyloid β₁-42, Nrf-2, HO-1, NF-κB, NLRP3, IL-1β, TNF-α, Caspase-3, and IDE in the Hippocampus. Mouse ELISA kits for Ach (Cat. # MBS733116), MDA (Cat. # MBS269473), Nrf-2 (Cat. # MBS2516218), HO-1 (Cat. # MBS760394), NF-κB (Cat. # MBS2023542), NLRP3 (Cat. # MBS920134), caspase-3 (Cat. # MBS733100), and IDE (Cat. # MBS2019335) were obtained from Mybiosource (San Diego, CA, USA). Mouse ELISA kits for amyloid β₁-42 (Cat. # KMB3441), IL-1β (Cat. # BMS6002), and TNF-α (Cat. # BMS607-3) were purchased from Invitrogen (Carlsbad, CA, USA). All procedures were performed according to the manufacturer’s instructions. The results were expressed as ng/mg protein for Ach, Nrf-2, NLRP3, and caspase-3, as pg/mg protein for HO-1, amyloid β₁-42, NF-κB, IL-1β, TNF-α, and IDE, and as nmol/mg protein for MDA.

2.7.2. Colorimetric Determination of GSH. GSH, an antioxidant peptide, was assessed using a colorimetric kit (Biodiagnostics, Cairo, Egypt). Briefly, 0.1 ml of the hippocampal homogenate was mixed with 0.5 ml of trichloroacetic acid (500 nmol/L) and left for 5 min for precipitation of protein SH-groups. Then, the solutions were centrifuged at 3000 rpm for 15 min. After centrifugation, 0.5 ml of a protein-free supernatant was added to 1 ml of phosphate buffer solution (100 mmol/L) and 0.1 ml of 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB) (1 mmol/L), which is reduced by GSH to form a stable yellow product (5-mercapto-2-nitrobenzoic acid) (DTNB) (1 mmol/L). The absorbance was measured at 412 nm after 5-10 min against blank, which was similarly prepared using 0.5 ml of distilled water instead of the sample, using a double beam computerized spectrophotometer (Thermo Electron Corporation, evolution 100, Altrincham, England). GSH concentration was calculated from the following equation and was expressed as mmol/mg protein.

\[
\text{GSH concentration} = \frac{\text{absorbance of the sample} \times 2.22}{\text{mg tissue used}}.
\]

2.7.3. Western Blot Analysis of Phosphorylated Tau, GSK-3β, and mTOR Protein Expression in the Hippocampus. Protein solutions were extracted from hippocampal tissues; then, equal amounts of protein were attached onto a sodium dodecyl sulfate-polyacrylamide gel to be separated by electrophoresis according to their molecular weight. After electrophoresis, proteins were transferred to a nitrocellulose membrane (Amersham Bioscience, Piscataway, NJ, USA) using semidry transfer apparatus (Bio-Rad, Hercules, CA, USA). The membranes’ nonspecific binding sites were then blocked by soaking in 5% skimmed milk. Next, the membranes were incubated at 4°C overnight on a roller shaker with solutions containing antiphosphorylated tau (1:10000, Cat. # ab109390), anti-GSK-3β (1:5000, Cat. # ab32391), and anti-mTOR (1:10000, Cat. # ab134903), which were obtained from Abcam (Cambridge, MA, USA). The membranes were then washed and incubated with the horseradish peroxidase-conjugated secondary antibody solution. Finally, the blots were developed with enhanced chemiluminescence detection reagents (Amersham Biosciences, Arlington Heights, IL, USA). Scanning laser densitometry (GS-800 system, Bio-Rad, Hercules, CA, USA) was used to determine the quantities of the target proteins. The results were normalized with β-actin protein expression and expressed as arbitrary units.

2.7.4. Quantitative Real-Time Polymerase Chain Reaction Analysis of ERK1/2 and p38-MAPK Gene Expression in the Hippocampus. RNA was extracted; then, 1 μg was reverse-transcribed into complementary DNA using an RT-PCR kit (Stratagene, Cat. # 600188, La Jolla, CA, USA) according to the manufacturer’s instructions. Quantitative RT-PCR was accomplished using SYBR Green JumpStart Taq ReadyMix (Sigma–Aldrich, Cat. # SS193, St. Louis, MO, USA), where 5 μl of complementary DNA was added to 12.5 μl of SYBR Green, 5.5 μl of RNase free water, and 2 μl of each primer (5 pmol/μl). The primer sequences are shown in Table 1. The PCR reactions comprised 40 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 60 s, and extension at 72°C for 60 s. The 2^−ΔΔCT formula was applied to determine the relative expression of target genes, using β-actin as a control.

2.7.5. Determination of Protein Content. The protein content was quantified according to the method described by Lowry et al. [35].

2.8. Histopathological Examination. Brains were carefully separated, washed with ice-cold saline, and immediately fixed in 10% formalin for 24 h. The brains were then washed,
Dehydrated in alcohol, and embedded in paraffin blocks. Tissue sections of 4 μm were stained with H & E for preliminary histopathological examination. Congo red stain was applied to detect amyloid plaques, and Nissl stain was used to assess neurodegeneration in the cerebral cortex and the hippocampal regions: the cornu ammonis (CA3&4) and the dentate gyrus (DG), according to the method described by Nobakht et al. [36].

2.9. Statistical Analysis. All data were checked for normality and homogeneity of variance using Shapiro-Wilk and Brown-Forsythe tests, respectively. Datasets that fulfilled the assumptions for parametric analysis were analyzed using one-way ANOVA followed by Tukey’s multiple comparisons test and were expressed as mean ± SD. The amyloid plaque number was analyzed using Kruskal–Wallis nonparametric test followed by Dunn’s multiple comparisons test and was expressed as median and range. The mean escape latency in the MWM was analyzed by two-way ANOVA. A probability level of less than 0.05 was accepted as being significant in all statistical tests. Statistical analysis was performed using GraphPad Prism software version 8 (San Diego, CA, USA).

3. Results

3.1. PFT Ameliorated STZ-Induced Cognitive Impairment. In the NOR test, STZ significantly deteriorated memory in mice as compared with the sham control group (p < 0.0001) (Figure 2). PFT administration (100, 300, and 600 mg/kg) improved cognitive performance in a dose-dependent manner, which was revealed by a significant increase in the discrimination (2.5%, 39.1%, and 57.9%, respectively) and preference (95.5%, 127.2%, and 166.1%, respectively) indices as compared with the STZ group (t (5, 66) = 281.6 and 58.5, respectively, p < 0.0001). The effect of PFT was comparable to that of simvastatin, which significantly increased the
discrimination (by 27.9%) and preference indices (by 79.4%) as compared with the STZ group.

On the first day of training in the MWM, there was no significant difference in the mean escape latency between the STZ and treated groups. From the second day until the fourth day, the mice in the treatment groups took a shorter period of time to reach the platform as compared with the STZ group. On the test day, animals treated with PFT (100, 300, and 600 mg/kg) displayed a substantial increase in the time spent in the target quadrant in which the platform was previously located (2.9-, 3.4-, and 4-fold, respectively) as compared with the STZ group (F(5, 66) = 125, p < 0.0001). The effect of PFT was in line with that of simvastatin (2.5-fold increase as compared with the STZ group) (Figure 2).

3.2. PFT Reversed STZ-Induced Alterations in Ach and Amyloid β1-42 Levels in the Hippocampus. Mice that received STZ showed a large decline in Ach levels and an increase in amyloid β1-42 level in the hippocampus as compared to their sham control counterparts (F(5, 30) = 21.9 and 146, respectively, p < 0.0001) (Figure 3). Improvements in cognition by PFT (100, 300, and 600 mg/kg) were reflected by augmentation of hippocampal Ach by 2.4-, 2.9-, and 3-fold, respectively, and suppression of amyloid β1-42 by 34.1%, 45.3%, and 52.5%, respectively, as compared with the STZ group (p < 0.001 and p < 0.0001). These results reflected those exhibited by simvastatin (increase in Ach by 2.4-fold and decrease in amyloid β1-42 by 43.4% as compared with STZ group).

3.3. PFT Attenuated STZ-Induced Oxidative Stress. Mice that received STZ exhibited a significant elevation in MDA level (F(5, 30) = 52.9) and a reduction in Nrf-2 level, HO-1 level, and GSH activity in the hippocampus as compared with the sham control group (F(5, 30) = 37.3, 174.4, and 274.2, respectively) (p < 0.0001) (Figure 4). PFT (100, 300, and 600 mg/kg) suppressed the MDA level by 35.2%, 56.2%, and 68.8%, respectively, and restored Nrf-2 level by 2.2-, 2.8-, and 3.8-fold, respectively, as well as HO-1 level by 3.3-, 4.2-, and 5.3-fold, respectively, and GSH activity by 2.1-, 2.5-, and 2.8-fold, respectively, as compared to STZ-exposed mice (p < 0.0001). The effect of PFT on MDA level (57.1%) as well as Nrf-2 (2.7-fold), HO-1 (4.7-fold), and GSH activity (2-fold) was similar to that of simvastatin in STZ animals.

3.4. PFT Mitigated STZ-Induced Inflammatory Changes. STZ ICV injection caused an obvious increase in different inflammatory markers, including NF-κB, NLRP3, IL-1β, and TNF-α, in the hippocampus as compared with the sham control group (F(5, 30) = 21.7, 68.7, 262.7, and 82.5, respectively, p < 0.0001) (Figure 5). PFT treatment (100, 300, and 600 mg/kg) significantly decreased the levels of NF-κB by 37%, 41.8%, and 50.1%, respectively, as well as NLRP3 (20.1%, 48.4%, and 50.3%, respectively), IL-1β (43.8%, 50.1%, and 50.6%, respectively), and TNF-α (39.2%, 43.6%, and 59.7%, respectively) as compared with the STZ group (p < 0.001 and p < 0.0001). The effects of PFT on these markers were similar to those of simvastatin, which decreased NF-κB by 49.1%, NLRP3 by 33.1%, IL-1β by 48.2%, and TNF-α by 50.6%.

3.5. PFT Alleviated STZ-Induced Alterations in Caspase-3 Level in the Hippocampus. In mice that received STZ, the hippocampal caspase-3 level was significantly higher in comparison to the sham control group (F(5, 30) = 37.8, p < 0.0001) (Figure 6), an effect that was ameliorated by PFT treatment (100, 300, and 600 mg/kg), which decreased the caspase-3 level by 53%, 59.2%, and 63.9%, respectively, as compared with the STZ group (p < 0.0001). The activity of PFT was
comparable to that of simvastatin, which hampered caspase-3 activity by 59.2%.

3.6. PFT Inverted STZ-Induced Alterations in the IDE Level in the Hippocampus. IDE, a key Aβ degrading enzyme, was also examined. STZ injection caused an obvious decline in IDE level in the hippocampus as compared with the sham control group ($F(5, 30) = 183.8, p < 0.0001$) (Figure 7). Supplementation with PFT (100, 300, and 600 mg/kg) significantly raised the level of IDE 1.5-, 1.6-, and 1.8-fold, respectively, as compared with the STZ group ($p < 0.0001$), an effect that was comparable to that of simvastatin in STZ mice (1.3-fold).

3.7. PFT Amended the Changes Induced by STZ in Phosphorylated Tau, ERK1/2, p38-MAPK, GSK-3β, and mTOR Expression in the Hippocampus. STZ significantly elevated the expression of phosphorylated tau ($F(5, 12) = 130.2$), ERK1/2 ($F(5, 12) = 104.2$), p38-MAPK ($F(5, 12) = 121.7$), GSK-3β ($F(5, 12) = 216.6$), and mTOR ($F(5, 12) = 132.1$) in the hippocampus as compared with the sham control group ($p < 0.0001$) (Figure 8). PFT administration (100, 300, and 600 mg/kg) significantly ameliorated the expression of phosphorylated tau (47%, 51.8%, and 54.3%, respectively), ERK1/2 (51.3%, 53%, and 70.4%, respectively), p38-MAPK (55%, 55%, and 71.8%, respectively), GSK-3β (52.3%, 60.4%,...
and 66.7%, respectively), and mTOR (41%, 38.5%, and 37.2, respectively) in the hippocampus as compared with the STZ group (p < 0.0001). The favorable outcomes of PFT treatment were comparable to those of simvastatin, which diminished the expression of phosphorylated tau by 45.9%, ERK1/2 by 69.1%, p38-MAPK by 68.8%, GSK-3β by 69.2%, and mTOR by 43.4% in AD mice.

3.8. PFT Rescued STZ-Induced Histological Alterations. Histopathological examination after H & E staining of the sham control group showed normal histological structures in the cerebral cortices and hippocampi. Meanwhile, the STZ group showed widespread neuronal degeneration and neurophagia along with activated microglia cells, inflammatory cell infiltration, and diffuse hemorrhages. Simvastatin-treated mice brains had apparently normal neurons with some scattered degenerated neurons and a small number of lymphocyte aggregations. PFT-treated (100 mg/kg) mice brains showed some degenerated neurons that were associated with multifocal areas of hemorrhages. However, mice treated with 300 mg/kg of PFT showed apparently normal structures, except for severely congested blood vessels and some degenerated neurons in the CA3 and CA4 regions. The high dose of PFT (600 mg/kg) conferred the best protection and closely reflected the effects of simvastatin treatment, where the cerebral cortex and hippocampus showed an

**Figure 5:** PFT mitigated STZ-induced inflammatory changes. Each bar with vertical line represents the mean ± SD of 6 mice per group: * significantly different from the sham control group at p < 0.05, ** significantly different from the sham control group at p < 0.01, **** significantly different from the sham control group at p < 0.0001, #### significantly different from STZ group at p < 0.0001 using one-way ANOVA followed by Tukey’s multiple comparisons test.
apparently normal structure except for some individual degenerated cells in the CA3 region (Figure 9).

Cerebral cortex and hippocampus tissues were also examined for amyloid plaques, which were stained with Congo red. The results (Figure 10) showed that the sham control group had no amyloid deposition in the examined tissue sections. In contrast, the model group had a significantly high number of plaques in the cerebral cortex and hippocampus as compared with the sham control group (test statistic \( t = 41.1 \), \( p < 0.001 \)). However, PFT (100, 300, and 600 mg/kg) and simvastatin treatment conferred a marked reduction in the number of amyloid plaques as compared with STZ. The data regarding the amyloid plaques in the cerebral cortex and hippocampus are shown in Table 2.

Neurodegeneration was examined in the brain sections that were treated with Nissl stain, and the percentage of intact neurons was calculated as the survival rate. The results are summarized in Table 2. STZ resulted in a severe loss of neurons in the cerebral cortex and hippocampal regions CA3, CA4, and DG as compared with the sham control group \( F(5,12) = 360.7, 288.8, 696.6, \) and 592.6, respectively, \( p < 0.0001 \)). Treatment with PFT significantly conserved neurons in the cerebral cortex (1.6-, 1.8-, and 1.9-fold, respectively) and the hippocampus (CA3: 2.8-, 3-, and 3.1-fold, respectively; CA4: 2-, 2.2-, and 2.5-fold, respectively; DG: 2-, 2-, and 2.23-fold, respectively) as compared with the STZ group (Figure 11). The effects of PFT corresponded to those of simvastatin, which preserved neurons in the cerebral cortex 2-fold and in CA3, CA4, and DG 3-, 2.3-, and 2.3-fold, respectively.

The purpose of the current study was to address the role of gut microbiome modulation through the administration of the natural dietary product, PFT, in the prevention or improvement of AD symptoms in an STZ-induced AD mouse model. This was inspired by recent approaches that focus on the investigation of natural products present in diet as vital bioactive molecules against neurodegenerative diseases [37]. It was revealed that PFT could significantly improve cognitive impairment and dementia, prevent neuronal degeneration in the cortex and hippocampus, restore hippocampal Ach levels, and decrease the presence of amyloid plaques and disease biomarkers in a dose-dependent manner. Our experimental evidence suggests that PFT supplementation attenuates cognitive dysfunction by targeting oxidative stress and inflammatory and apoptotic pathways. Moreover, PFT enhanced the hippocampal level of IDE, a key Aβ-degrading enzyme, with a subsequent decrease in Aβ level in the hippocampus and an improvement in memory deficiency in the STZ-induced AD animal model. Furthermore, PFT significantly reduced tau hyperphosphorylation via suppression of ERK1/2, p38-MAPK, GSK-3β, and mTOR, the chief kinases that regulate tau’s hyperphosphorylation. Our results demonstrate that the remarkable effects of PFT in attenuating AD symptoms were comparable to those of simvastatin, a drug whose therapeutic effects have been empirically proven for AD. Notably, simvastatin has been shown in several studies to improve cognitive performance, reduce the levels of Aβ peptides, and prevent neuronal loss in AD through its ability to reduce oxidative stress, inflammation, and apoptosis along with the promotion of IDE secretion and modulation of the PI3K/Akt and MAPK/ERK1/2 pathways [38–41].

**4. Discussion**

![Figure 6: PFT alleviated STZ-induced alterations in caspase-3 level in the hippocampus. Each bar with vertical line represents the mean ± SD of 6 mice per group; * significantly different from the sham control group at \( p < 0.05 \), **** significantly different from the sham control group at \( p < 0.0001 \). The data regarding the amyloid plaques and disease biomarkers in a dose-dependent manner.](image1.png)

![Figure 7: PFT inverted STZ-induced alterations in the IDE level in the hippocampus. Each bar with vertical line represents the mean ± SD of 6 mice per group; **** significantly different from the sham control group at \( p < 0.0001 \).](image2.png)
The ICV-STZ-induced AD model is considered to sufficiently mimic the progressive pathology of AD in the human brain [42]. In this context, STZ conferred most of the features of AD, with progressive deficits in learning, memory, and cognitive behavior, along with aggregation of Aβ and neuron loss in the cortex and hippocampus, and a massive reduction in hippocampal Ach level, in line with former studies [26, 43, 44]. Aβ accumulation and plaque development are the major biomarkers for the detection of AD, where Aβ1-42 is the most abundant form of Aβ protein and is deposited early as plaques [45]. The molecular mechanisms that trigger the aggregation of Aβ in AD are not fully understood; however, dysbiosis is implicated [8]. Under conditions of dysbiosis, bacteria that inhabit the microbiome release mixtures of lipopolysaccharides, amyloids, and other microbial exudates into their proximal environment. These exudates may leak from the gastrointestinal tract due to increased gut permeability induced by dysbiosis and then accumulate in the brain [8, 9]. It is worth mentioning that aging makes the involvement of gut microbiota in amyloid development and propagation more significant, since both the gut and the blood-brain

**Figure 8:** PFT amended the changes induced by STZ in phosphorylated tau, ERK1/2, p38-MAPK, GSK-3β, and mTOR expression in the hippocampus. Each bar with vertical line represents the mean ± SD of 3 mice per group; *significantly different from the sham control group at p < 0.05, **significantly different from the sham control group at p < 0.01, ***significantly different from the sham control group at p < 0.0001, ****significantly different from STZ group at p < 0.0001 using one-way ANOVA followed by Tukey’s multiple comparisons test.
barrier become more permeable to small molecules during aging [46]. In this study, investigation of the Aβ1-42 isoform revealed steep elevation of Aβ1-42 in the hippocampi of STZ-treated mice, an effect that was reversed by modulation of the gut microbiota through supplementation with PFT. Additionally, dysbiosis is associated with alterations in the levels of certain neurotransmitters, including Ach [6]. Cognitive function was revealed to be regulated by Ach, which employs its effect on the striatum, hippocampus, and amygdala [47]. The hippocampus is the core brain region involved in memory and learning processes [48]. Thus, declined cholinergic function in the hippocampus causes cognitive impairments together with learning and memory insufficiencies [44]. In our results, we found that STZ treatment resulted in neuronal degeneration and neuronophagia (arrows) (c) (magnification ×40), perivascular lymphocytic cuffing in the cerebral cortex (d) (magnification ×20), thickened blood vessel wall (arrow) (e) (magnification ×40), expanded meninges by extensive hemorrhage and inflammatory exudates (f) (magnification ×20), dark shrunken degenerated neurons in CA3 and CA4 of the hippocampus (g), and endothelial capillary proliferation in the striatum (h) (magnification ×20). Mice receiving simvastatin showed apparently normal structure of the cerebral cortex (i) (magnification ×20), small aggregation of lymphocytes (j) (magnification ×20), diffuse astroglisis with lymphocytic infiltration in the cerebral cortex (n), vascular congestion in the cerebral cortex (o), and vascular congestion in the striatum layer (p) (magnification ×20). Brain of PFT (300 mg/kg) showed vascular congestion in the cerebral cortex (q) (magnification ×10), and apparently normal neurons and few scattered degenerated neurons in the CA1 of the hippocampus (r) (magnification ×20). Brain of PFT (600 mg/kg) displayed apparently normal cerebral cortex (s) and individual degenerated neurons in the CA3 of the hippocampus (t) (magnification ×20).
in an obvious decrease in hippocampal Ach level, which was accompanied by spatial and short-term memory impairment. Conversely, the administration of PFT in mice with STZ-induced cognitive deficiency prevented this decrease in Ach concentration, with a subsequent improvement in memory and learning, as exemplified by the significant elevation in discrimination and preference indices in the NOR test and the increase in the time spent by mice in the target quadrant during the MWM test probe trial. This valuable effect could be attributed to the restoration of gut microbiota along with the ability of Lactobacillus, the main component of PFT, to yield Ach and to hinder acetylcholinesterase enzyme [49, 50]. The potential effect of PFT treatment was similar to that of simvastatin treatment in STZ-treated mice. The positive effect of simvastatin on cognition is attributed to the restoration of cholesterol homeostasis, since elevated cholesterol levels may result in Aβ formation and cognitive impairment [38]. In addition, the protective effects of simvastatin may also be related to its ability to diminish brain ischemia, prevent cholinergic neuronal loss, modulate brain-derived neurotrophic factor expression, and promote nitric oxide synthesis [28].

Oxidative stress is a chief contributor to aging and age-related diseases including AD [51]. According to hormesis (a dose-response phenomenon, characterized by low-dose stimulation and high-dose inhibition), temporary exposure of neurons to low levels of reactive oxygen species (ROS) has a protective effect, due to the activation of transcriptional regulators called vitagenes that endorse cell adaptive mechanisms to maintain homeostasis and to protect against more severe oxidative stress; nevertheless, chronic exposure to oxidative stress with massive generation of ROS leads to
significant damage to cellular functions, which eventually results in the initiation of AD [52–54]. The absence of gut microbes is associated with oxidative aging. Stress has also been associated with an increase in gut permeability. Under normal circumstances, the gut microbiota produces antioxidants. However, during dysbiosis, lipopolysaccharides and amyloid dissemination cause an increase in ROS along with an induction of oxidative stress [6, 8]. This, in turn, leads to cognitive impairment since the hippocampus, which regulates cognitive function, is highly vulnerable to oxidative stress [55]. In the present study, STZ was associated with marked oxidative stress, which could possibly be attributed to its ability to induce ROS. This reduction in antioxidant capacity is associated with neuronal damage and consequential cognitive deterioration which was observed in STZ-treated mice. These findings are in agreement with a recent study [44]. Remarkably, PFT acted as a potent antioxidant, which was evidenced by a reduction in MDA content (indicator of lipid peroxidation) and activation of Nrf-2 transcription factor with subsequent induction of its target genes HO-1 and GSH in the hippocampi of STZ-treated mice. Notably, Nrf-2 plays a vital role in suppressing oxidative stress and inflammation through regulation of vignate transcription, such as HO-1 and glutamate-cysteine synthetase that synthesize GSH, which display antioxidant activity and abate various forms of stress, thus maintaining redox balance and homeostasis [37, 56]. The antioxidant property of PFT was further confirmed by the protection of the brain from Aβ neurotoxicity and the restoration of memory. Numerous studies have suggested that the Lactobacillus in PFT produces exopolysaccharide, which displays high scavenging activity against ROS, increases the activity of antioxidant enzymes, and enhances the overall antioxidant capacity [57, 58]. The antioxidant activity displayed by PFT was equivalent to that exerted by simvastatin. In addition to its direct antioxidant effect, simvastatin has been proven to reduce circulating oxidized low-density lipoproteins and circulating markers of oxidation (such as nitrotyrosine), inhibit oxidant enzymes, and upregulate antioxidant enzyme activity [59].

Besides oxidative stress, inflammation also plays a fundamental role in the pathogenesis of AD [60]. Microglial activation and high levels of proinflammatory cytokines, such as interleukins and TNF-α, have been detected in the serum of AD patients [61]. Dysbiosis contributes to the pathogenesis of AD partly through the generation of a neuroinflammatory state [62]. It has been suggested that an increase in gut permeability following dysbiosis may lead to neuroinflammation and subsequent hippocampal damage [63]. After leaking from the gut, bacteria-derived polysaccharides and amyloids activate NF-κB signaling. NF-κB in turn stimulates proinflammatory microRNA-34a release, which reduces the expression of TREM2 (triggering receptor expressed on myeloid cells 2), resulting in phagocytosis dysfunction and accumulation of Aβ [64]. Furthermore, lipopolysaccharides and amyloids can endorex gut leakiness and trigger ROS in the brain with subsequent microglial activation that enhances proinflammatory cytokine release [65, 66]. It is worth mentioning that ROS and microglial activation along with dysregulation of redox homeostasis by suppression of Nrf-2 transcription results in stimulation of NF-κB signaling, which triggers elevation of TNF-α and upregulation of NLRP3 [37, 67, 68]. NLRP3 inflammasome activation contributes to the inflammatory events in AD pathogenesis, since it enhances the secretion of IL-1β, which further promotes microglial activation and accumulation of inflammatory and neurotoxic factors resulting in a vicious cycle that exacerbates neurodegeneration [67]. To this end, modulating the gut microbiome with probiotics may represent an effective strategy to diminish the level of chronic inflammation and Aβ associated with AD. In this context, STZ treatment resulted in marked neuroinflammation, which was efficiently inhibited by PFT supplementation as verified by the substantial decrease in the expression of hippocampal levels of NF-κB, NLRP3, IL-1β, and TNF-α in STZ-treated mice, with consequent amelioration of Aβ burden in the hippocampus. The anti-inflammatory effect of PFT corresponded to that of simvastatin, which has been shown to inhibit inflammation by reducing neutrophil infiltration, nitrotyrosine formation, NF-κB activation, and inducible nitric oxide synthase expression [69].

Immensely neuronal loss is among the pathological features of AD. Apoptosis, a vital aspect of AD pathogenesis,
is responsible for AD-associated neuronal death [70]. This phenomenon has been assumed to be due to the presence of apoptotic factors in AD brain tissue, in addition to the fact that the brain is highly vulnerable to apoptotic damage [71]. Caspase-3, the major source of apoptotic cell death in neurodegenerative diseases, is directly involved in AD apoptosis [72]. Remarkably, the microbiota can regulate apoptosis via gut-brain axis signaling [73]. In dysbiosis, harmful signals are propagated, leading to increased ROS production and inflammation with consequent mitochondrial dysfunction, which endorses cytochrome c release, thus triggering caspase-3 and inducing apoptosis and neuronal death [74].

In the present study, administration of PFT effectively attenuated the activity of caspase-3 in AD mice, an effect that was associated with neuronal preservation in the hippocampal structures and relevant restoration of attentional performance. PFT’s antiapoptotic activity was comparable to simvastatin’s effects in STZ-treated mice. Simvastatin has been shown to attenuate the pathology of AD due to its antia apoptotic effects in hippocampal cells [75].

Insulin has also been linked with AD pathology [76]. In this context, elevated insulin levels have been observed in AD brains, resulting in exaggerated inflammatory responses and accumulation of Aβ in the brain [77]. Besides stimulating Aβ secretion, insulin inhibits Aβ degradation by competing for IDE, the key regulator of Aβ in neurons [78]. Insulin not only exerts a direct effect on Aβ metabolism but also promotes mitochondrial dysfunction, oxidative stress, and apoptosis, all of which contribute to the development of AD [79]. In particular, the absence of gut microbes may lead to the development of insulin resistance and the suppression of IDE, which are both found in AD [80]. In this study, restoration of the gut microbiota via PFT supplementation enhanced IDE and significantly decreased Aβ levels in STZ-treated rats. In AD mice, PFT mediated IDE secretion as effectively as simvastatin, which has been reported to affect IDE via an unconventional autophagy-based secretory pathway [40].

Tau hyperphosphorylation is greatly implicated in AD pathogenesis [81]. Tau is a microtubule-binding protein that is responsible for the assemblage and stabilization of microtubules [82]. Pathological tau protein is abnormally hyperphosphorylated and accumulated forming neurofibrillary tangles, a hallmark of AD [82]. Tau phosphorylation is regulated by multiple kinases and phosphatases. ERK1/2, p38-MAPK, GSK-3β, and mTOR are the main kinases that are involved in tau hyperphosphorylation, while protein phosphatase 2A (PP2A) is the chief phosphatase that dephosphorylates tau [83, 84]. It has been demonstrated that the aforementioned kinases are highly activated in AD brains along with the declined activity of PP2A [81, 84]. Of note, Aβ and oxidative stress have been shown to stimulate MAPK

Figure 11: Sections of the cerebral cortex and the hippocampal regions (CA3, CA4, and DG) stained with Nissl stain. The sham control group showed normal intact neurons in all brain regions. An increased number of dark and shrunken neurons with pyknotic nuclei (arrows) was detected in the STZ group, and fewer numbers were recorded in other treated groups (magnification ×20).
kinase (MEK), which activates ERK1/2 and p38-MAPK through phosphorylation, thereby resulting in tau hyperphosphorylation and prominent neurofibrillary tangle formation [85, 86]. Moreover, Aβ and insulin resistance suppress phosphatidylinositol-4,5-bisphosphate 3-kinase-(PI3K)-Akt signaling leading to activation of GSK-3β and mTOR, which in turn causes PP2A inhibition and subsequent tau hyperphosphorylation [77]. Importantly, there is evidence that activation of mTOR promotes Aβ deposition through the inhibition of autophagy and disposes insulin resistance, thus leading to further tau phosphorylation, resulting in a vicious cycle that aggravates AD [87]. It has been proposed that gut microbiota alteration is associated with tau hyperphosphorylation, based on the fact that factors that enhance tau hyperphosphorylation, including Aβ, oxidative stress, and insulin resistance, are precipitated by dysbiosis [88, 89]. In addition, dysbiosis can induce leucine metabolism disorder, which enhances mTOR activity [90, 91]. Consequently, gut microbiome restoration could dampen tau hyperphosphorylation. Our study shows that PFT decreased tau phosphorylation along with downregulation of ERK1/2, p38-MAPK, GSK-3β, and mTOR expression in the hippocampi of STZ-treated mice, and this favorable effect was accompanied by suppression of Aβ accumulation and enhancement of cognitive function. The action of PFT was parallel to that of simvastatin, which has been demonstrated to modulate the PI3K/Akt and MAPK/ERK1/2 pathways and halt neurodegeneration [39, 92].

5. Conclusions

This study reveals that the gut microbiota affects learning and memory via the microbiota-gut-brain axis and that AD is highly related to alterations in the gut microbiota composition. The delivery of Lactobacillus via PFT, a kefir product, displayed several benefits in STZ-induced AD mice. We have demonstrated that PFT not only improves cognitive function along with amelioration of histopathological markers but also attenuates oxidative stress, suppresses neuroinflammation, reduces apoptosis, and enhances IDE. Thus, PFT ameliorates multiple factors that underlie AD pathology. As a safe, nontoxic agent, PFT represents a useful potential therapy for AD.

Data Availability

The data of the present study including the figures and western blot analysis used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare there are no conflicts of interest.

Authors’ Contributions

N El Sayed, E. Kandil, and M Ghoneum planned the study and wrote the manuscript. N El Sayed designed and performed the experiments. All authors revised and approved the manuscript.

Acknowledgments

PFT was provided by Paitos Co., Ltd., Yokohama, Kanagawa, Japan. This work was funded by Paitos Co., Ltd., Yokohama, Kanagawa, Japan; Grant #T0099108.

References

[1] X. Hu, T. Wang, and F. Jin, “Alzheimer’s disease and gut microbiota,” Science China. Life Sciences, vol. 59, no. 10, pp. 1006–1023, 2016.
[2] W. Jagust, “Imaging the evolution and pathophysiology of Alzheimer disease,” Nature Reviews. Neuroscience, vol. 19, no. 11, pp. 687–700, 2018.
[3] S. H. Xin, L. Tan, X. Cao, J. T. Yu, and L. Tan, “Clearance of amyloid beta and tau in Alzheimer’s disease: from mechanisms to therapy,” Neurotoxicity Research, vol. 34, no. 3, pp. 733–748, 2018.
[4] V. H. Finder, “Alzheimer’s Disease: A General Introduction and Pathomechanism,” Journal of Alzheimer’s Disease, vol. 22, no. s3, pp. S5–S19, 2010.
[5] X. K. Tong, C. Lecrux, P. Rosa-Neto, and E. Hamel, “Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits,” The Journal of Neuroscience, vol. 32, no. 14, pp. 4705–4715, 2012.
[6] F. Angelucci, K. Cechova, J. Amlerova, and J. Hert, “Antibiotics, gut microbiota, and Alzheimer’s disease,” Journal of Neuroinflammation, vol. 16, no. 1, p. 108, 2019.
[7] A. Parker, S. Fonseca, and S. R. Carding, “Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health,” Gut Microbes, vol. 11, no. 2, pp. 135–157, 2020.
[8] F. Pistollato, S. Sumalla Cano, I. Elio, M. Masias Vergara, F. Giampieri, and M. Battino, “Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease,” Nutrition Reviews, vol. 74, no. 10, pp. 624–634, 2016.
[9] Y. Zhao, P. Dua, and W. J. Lukiw, “Microbial sources of amyloid and relevance to amyloidogenesis and Alzheimer’s Disease (AD),” Journal of Alzheimer’s Disease & Parkinsonism, vol. 5, no. 1, 2015.
[10] Y. Zhao, V. Jaber, and W. J. Lukiw, “Secretory products of the human GI tract microbiome and their potential impact on Alzheimer’s disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus,” Frontiers in Cellular and Infection Microbiology, vol. 7, 2017.
[11] S. Athari Nik Azm, A. Dzazayeri, M. Safa et al., “Lactobacilli and bifidobacteria ameliorate memory and learning deficits and oxidative stress in β-amyloid (1–42) injected rats,” Applied Physiology, Nutrition, and Metabolism, vol. 43, no. 7, pp. 718–726, 2018.
[12] M. Ghoneum and J. Gimzewski, “Apoptotic effect of a novel kefir product, PFT, on multidrug-resistant myeloid leukemia cells via a hole-piercing mechanism,” International Journal of Oncology, vol. 44, no. 3, pp. 830–837, 2014.
[13] Y. Yabumoto, H. Tani, K. Suzuki, T. Yabumoto, and Y. Yoshida, Novel fermented milk product and use thereof U.S. Patent No US 2011/0123640 A1, Fiss KK, 2011.
[14] D. Kaushal and V. K. Kansal, “Probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum alleviates age-influenced oxidative stress and improves expression of biomarkers of aging in mice,” *Molecular Biology Reports*, vol. 39, no. 2, pp. 1791–1799, 2012.

[15] X. Lin, Y. Xia, G. Wang et al., “Lactobacillus plantarum AR301 alleviates the oxidative stress of D-galactose-induced aging mice liver by upregulation of Nrf2-mediated antioxidant enzyme expression,” *Journal of Food Science*, vol. 83, no. 7, pp. 1990–1998, 2018.

[16] P. Carasi, S. Racedo, and C. J. J. of immunology, “Impact of kefir derived lactobacillus kefiri on the mucosal immune response and gut microbiota,” 2015, http://hindawi.com.

[17] Y. Sun, Y. Huang, F. Ye et al., “Effects of probiotics on glycemic control and intestinal dominant flora in patients with type 2 diabetes mellitus: a protocol for systematic review and meta-analysis,” *Medicine (Baltimore)*, vol. 99, no. 46, article e23039, 2020.

[18] N. K. Badr El-Din, S. M. Shaban, B. A. Abdulmajeed, and M. Ghoneum, “A novel kefri product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation,” *BMC Complementary Medicine and Therapies*, vol. 20, no. 1, p. 127, 2020.

[19] M. Ghoneum and reports, N. F.-O, N. Lester-Coll, E. J. Rivera, S. J. Soscia, K. Doiron, J. R. Wands, S. Vandresen-Filho, L. M. França, J. Alcantara-Junior et al., “PHD Study of the Central Corticotrophin-releasing factor2 receptors in behavioral, but not endocrine, response to environmental stress,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 302, no. 9242, pp. 1627–1631, 2000.

[20] M. Ghoneum and S. A.-I. J. of, “Reversal of age-associated oxidative stress in mice by PFT, a novel kefri product,” vol. 34, 2020http://journals.sagepub.com.

[21] D. L. Sparks, M. Sabbagh, D. Connor et al., “Statin therapy in Alzheimer’s disease,” *Acta Neurologica Scandinavica*, vol. 114, no. s185, pp. 78–86, 2006.

[22] H. Jick, G. L. Zornberg, S. S. Jick, S. Seshadri, and D. A. Drachman, “Statins and the risk of dementia,” *Lancet*, vol. 356, no. 9242, pp. 1627–1631, 2000.

[23] M. A. Pellemounter, M. Joppa, M. Carmouche et al., “Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 293, no. 3, pp. 799–806, 2000.

[24] M. A. Pellemounter, M. Joppa, N. Ling, and A. C. Foster, “Pharmacological evidence supporting a role for central corticotropin-releasing factor2 receptors in behavioral, but not endocrine, response to environmental stress,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 302, no. 1, pp. 145–152, 2002.

[25] G. Warmock, PHD Study of the Central Corticotrophin-Releasing Factor System Using the 2-Deoxyglucose Method for Measurement of Local Cerebral Glucose Utilisation, 2007.

[26] N. Lester-Coll, E. J. Rivera, S. J. Soscia, K. Doiron, J. R. Wands, and S. M. De La Monté, “Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease,” *Journal of Alzheimer’s Disease*, vol. 9, no. 1, pp. 13–33, 2006.

[27] N. O. Abdel Rasheed, N. S. el Sayed, and A. S. el-Khatib, “Targeting central B2 receptors ameliorates streptozotocin-induced neuroinflammation via inhibition of glycogen synthase kinase3 pathway in mice,” *Progress in Neuro-Psychopharmacology, vol. 86*, pp. 65–75, 2018.

[28] S. Vandresen-Filho, L. M. França, J. Alcantara-Junior et al., “Statins enhance cognitive performance in object location test in albino Swiss mice: involvement of beta-adrenoceptors,” *Physiology & Behavior*, vol. 143, pp. 27–34, 2015.

[29] H. Maeda, X. Zhu, S. Suzuki, K. Suzuki, and S. Kitamura, “Structural characterization and biological activities of an exopolysaccharide kefirin produced by Lactobacillus kefiranofaciens WT-2B T,” *Journal of Agricultural and Food Chemistry*, vol. 52, no. 17, pp. 5533–5538, 2004.

[30] M. Antunes and G. Biala, “The novel object recognition memory: neurobiology, test procedure, and its modifications,” *Cognitive Processing*, vol. 13, no. 2, pp. 93–110, 2012.

[31] L. M. Lueptow, “Novel object recognition test for the investigation of learning and memory in mice,” *Journal of Visualized Experiments*, vol. 2017, no. 126, pp. 1–9, 2017.

[32] A. Ennaceur, “One-trial object recognition in rats and mice: methodological and theoretical issues,” *Behavioural Brain Research*, vol. 215, no. 2, pp. 244–254, 2010.

[33] R. D’Hooge and P. P. de Deyn, “Applications of the Morris water maze in the study of learning and memory,” *Brain Research Reviews*, vol. 36, no. 1, pp. 60–90, 2001.

[34] G. L. Wenk, “Assessment of spatial memory using the radial arm maze and Morris water maze,” *Current Protocols in Neuroscience*, vol. 26, no. 1, 2004.

[35] O. H. Lowery, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” *The Journal of Biological Chemistry*, vol. 193, no. 1, pp. 265–275, 1951.

[36] M. Nobakht, S. M. Hoseini, P. Mortazavi et al., “Neuroprotective changes in brain cortex and hippocampus in a rat model of Alzheimer’s disease,” *Iranian Biomedical Journal*, vol. 15, no. 1–2, pp. 51–58, 2011.

[37] R. Siracusa, M. Scuto, R. Fusco et al., “Anti-inflammatory and anti-oxidant activity of Hidrox® in rotenone-induced Parkinson’s disease in mice,” *Antioxidants*, vol. 9, no. 9, p. 824, 2020.

[38] B. G. Schultz, D. K. Patten, and D. J. Berlau, “The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms,” *Translational Neurodegeneration*, vol. 7, no. 1, 2018.

[39] N. Yamamoto, Y. Fujii, R. Kasahara et al., “Simvastatin and atorvastatin facilitates amyloid β-protein degradation in extra-cellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK/Erk1/2 pathways,” *Glia*, vol. 64, no. 6, pp. 952–962, 2016.

[40] S. M. Son, S. Kang, H. Choi, and I. Mook-Jung, “Statins induce insulin-degrading enzyme secretion from astrocytes via an autophagy-based unconventional secretory pathway,” *Molecular Neurodegeneration*, vol. 10, no. 1, 2015.

[41] A. C. Tramontina, K. M. Wartchow, L. Rodrigues et al., “The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer’s disease in rats,” *Journal of Neural Transmission*, vol. 118, no. 11, pp. 1641–1649, 2011.

[42] C. Gao, Y. Liu, Y. Jiang, J. Ding, and L. Li, “Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced Alzheimer rat model,” *Brain Pathology*, vol. 24, no. 3, pp. 261–269, 2014.

[43] J. Kosaraju, C. C. Gali, R. B. Khatwal et al., “Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer’s disease,” *Neuropharmacology*, vol. 72, pp. 291–300, 2013.

[44] S. Hira, U. Saleem, F. Anwar, M. F. Sohail, Z. Raza, and B. Ahmad, “β-carotene: a natural compound improves
cognitive impairment and oxidative stress in a mouse model of streptozotocin-induced Alzheimer’s disease,” *Biomolecules*, vol. 9, no. 9, p. 441, 2019.

[45] J. T. Jarrett and P. T. Lansbury Jr., “Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer’s disease and scrapie?,” *Cell*, vol. 73, no. 6, pp. 1055–1058, 1993.

[46] D. K. Shoemark and S. J. Allen, “The microbiome and disease: reviewing the links between the oral microbiome, aging, and Alzheimer’s disease,” *Journal of Alzheimer’s Disease*, vol. 43, no. 3, pp. 725–738, 2015.

[47] S. R. Maratha and N. Mahadevan, “Memory enhancing activity of naringin in unstressed and stressed mice: possible cholinergic and nitriergic modulation,” *Neurochemical Research*, vol. 37, no. 10, pp. 2206–2212, 2012.

[48] E. Grober, C. B. Hall, R. B. Lipton, A. B. Zonderman, S. M. Resnick, and C. Kawas, “Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer’s disease,” *Journal of the International Neuropsychological Society*, vol. 14, no. 2, pp. 266–278, 2008.

[49] N. H. Musa, V. Mani, S. M. Lim, S. Vidyyaran, A. B. Abdul Majeed, and K. Ramasamy, “Lactobacilli-fermented cow’s milk attenuated lipopolysaccharide-induced neuroinflammation and memory impairment in vitro and in vivo,” *The Journal of Dairy Research*, vol. 84, no. 4, pp. 488–495, 2017.

[50] T. G. Dinan, Y. E. Borre, and J. F. Cryan, “Genomics of schizophrenia: time to consider the gut microbiome?,” *Molecular Psychiatry*, vol. 19, no. 12, pp. 1252–1257, 2014.

[51] S. Tarantini, C. H. T. Tran, G. R. Gordon, Z. Ungvari, and A. Caiszar, “Impaired neurovascular coupling in aging and Alzheimer's disease: Contribution of astrocyte dysfunction and endothelial impairment to cognitive decline,” *Experimental Gerontology*, vol. 94, pp. 52–58, 2017.

[52] D. J. Bonda, X. Wang, G. Perry et al., “Oxidative stress in Alzheimer disease: a possibility for prevention,” *Neuropharmacology*, vol. 59, no. 4–5, pp. 290–294, 2010.

[53] V. Calabrese, C. Cornelius, A. T. Dinkova-Kostova, E. J. Calabrese, and M. P. Mattson, “Cellular stress responses, the hormesis, gradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders,” *Antioxidants and Redox Signaling*, vol. 13, no. 11, pp. 1763–1811, 2010.

[54] S. Miquel, C. Champ, J. Day et al., “Poor cognitive ageing: vulnerabilities, mechanisms and the impact of nutritional interventions,” *Aging Research Reviews*, vol. 42, pp. 40–55, 2018.

[55] K. Marosi, Z. Bori, N. Hart et al., “Long-term exercise treatment reduces oxidative stress in the hippocampus of aging rats,” *Neuroscience*, vol. 226, pp. 21–28, 2012.

[56] S. Habtemariam, “The Nrfl2/HO-1 axis as targets for flavonones: neuroprotection by pinocembrin, naringenin, and eriocitrol,” *Oxidative Medicine and Cellular Longevity*, vol. 2019, 15 pages, 2019.

[57] C. Slattery, P. D. Cotter, and P. W. O’Toole, “Analysis of health benefits conferred by Lactobacillus species from kefir,” *Nutrients*, vol. 11, no. 6, pp. 1252, 2019.

[58] J. Zhang, X. Zhao, Y. Jiang et al., “Antioxidant status and gut microbiota change in an aging mouse model as influenced by exopolysaccharide produced by *Lactobacillus plantarum* YW11 isolated from Tibetan kefir,” *Journal of Dairy Science*, vol. 100, no. 8, pp. 6025–6041, 2017.

[59] J. Davignon, R. F. Jacob, and R. P. Mason, “The antioxidant effects of statins,” *Coronary Artery Disease*, vol. 15, no. 5, pp. 251–258, 2004.

[60] M. R. Minter, J. M. Taylor, and P. J. Crack, “The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease,” *Journal of Neurochemistry*, vol. 136, no. 3, pp. 457–474, 2016.

[61] E. Bagyinszky, V. V. Giau, K. Shim, K. Suk, S. S. A. An, and S. Y. Kim, “Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis,” *Journal of the Neurological Sciences*, vol. 376, pp. 242–254, 2017.

[62] C. Marques, M. Meireles, A. Faria, and C. Calhau, “High-fat diet–induced dysbiosis as a cause of neuroinflammation,” 2016, http://biologicalpsychiatryjournal.com.

[63] M. A. Daulatzai, “Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia,” *Neurochemical Research*, vol. 39, no. 4, pp. 624–644, 2014.

[64] Y. Zhao and W. J. Lukiw, “Microbiome-generated amyloid and potential impact on amyloidogenesis in Alzheimer’s disease (AD),” *Journal of Nature and Science*, vol. 1, no. 7, 2015.

[65] J. M. Hill and W. J. Lukiw, “Microbial-generated amyloids and Alzheimer’s disease (AD),” *Frontiers in Aging Neuroscience*, vol. 7, p. 9, 2015.

[66] E. A. Kandil, R. H. Sayed, L. A. Ahmed, M. A. Abd el Fattah, and B. M. el-Sayeh, “Modulatory role of Nur1 activation and thrombin inhibition in the neuroprotective effects of dabi-gatran etexilate in rotenone-induced Parkinson’s disease in rats,” *Molecular Neurobiology*, 2017.

[67] M. S. Tan, J. T. Yu, T. Jiang, X. C. Zhu, and L. Tan, “The NLRP3 inflammasome in Alzheimer’s disease,” *Molecular Neurobiology*, vol. 48, no. 3, pp. 875–882, 2013.

[68] O. A. Ahmedy, “Antiulcerogenic effect of melittin via mitigating TLR4/TRAf6 mediated NF-κB and p38MAPK pathways in acetic acid-induced ulcerative colitis in mice,” *Chemico-Biological Interactions*, p. 331, 2020.

[69] E. Esposito, B. Rinalli, E. Mazzon et al., “Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α,” *Journal of Neuroinflammation*, vol. 9, no. 1, 2012.

[70] J. H. Kim, “Brain-derived neurotrophic factor exerts neuroprotective actions against amyloid β-induced apoptosis in neuroblastoma cells,” *Experimental and Therapeutic Medicine*, vol. 8, no. 6, pp. 1891–1895, 2014.

[71] I. Ferrer, “Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer’s disease,” *Journal of Bioenergetics and Biomembranes*, vol. 41, no. 5, pp. 425–431, 2009.

[72] X. Gu, Z. Cai, M. Cai et al., “Protective effect of paoniflorin on inflammation and apoptosis in the cerebral cortex of a transgenic mouse model of Alzheimer’s disease,” *Molecular Medicine Reports*, vol. 13, no. 3, pp. 2247–2252, 2016.

[73] S. Westfall, N. Lomis, I. Kahouli, S. Y. Dia, S. P. Singh, and S. Prakash, “Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis,” *Cellular and Molecular Life Sciences*, vol. 74, no. 20, pp. 3769–3787, 2017.

[74] E. E. Noble, T. M. Hsu, and S. E. Kanoski, “Gut to brain dysbiosis: mechanisms linking western diet consumption, the microbiome, and cognitive impairment,” *Frontiers in Behavioral Neuroscience*, vol. 11, 2017.
[75] X. Hu, C. Song, M. Fang, and C. Li, “Simvastatin inhibits the apoptosis of hippocampal cells in a mouse model of Alzheimer’s disease,” *Experimental and Therapeutic Medicine*, vol. 15, no. 2, pp. 1795–1802, 2018.

[76] K. Talbot, H. Y. Wang, H. Kazi et al., “Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline,” *The Journal of Clinical Investigation*, vol. 122, no. 4, pp. 1316–1338, 2012.

[77] S. Gabbouj, S. Ryhänen, M. Marttinen et al., “Altered insulin signaling in Alzheimer’s disease Brain – Special emphasis on PI3K-Akt pathway,” *Frontiers in Neuroscience*, vol. 13, article 629, 2019.

[78] L. Zhao, B. Teter, T. Morihara et al., “Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention,” *The Journal of Neuroscience*, vol. 24, no. 49, pp. 11120–11126, 2004.

[79] S. Hauptmann, I. Scherping, S. Dröse et al., “Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice,” *Neurobiology of Aging*, vol. 30, no. 10, pp. 1574–1586, 2009.

[80] M. Al-Qahtani, A. G. Chaudhary, and E. I. Azhar, “Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease,” 2014, http://www.ingentaconnect.com.

[81] J. J. Pei, H. Braak, W. L. An et al., “Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer’s disease,” *Molecular Brain Research*, vol. 109, no. 1–2, pp. 45–55, 2002.

[82] C. Ballatore, V. M. Y. Lee, and J. Q. Trojanowski, “Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders,” *Nature Reviews Neuroscience*, vol. 8, no. 9, pp. 663–672, 2007.

[83] Veeranna, T. Kaji, B. Boland et al., “Calpain Mediates Calcium-Induced Activation of the Erk1,2 MAPK Pathway and Cytoskeletal Phosphorylation in Neurons: Relevance to Alzheimer’s Disease,” *The American Journal of Pathology*, vol. 165, no. 3, pp. 795–805, 2004.

[84] Y. Kitagishi, A. Nakanishi, Y. Ogura, and S. Matsuda, “Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer’s disease,” *Alzheimer’s Research & Therapy*, vol. 6, no. 3, p. 35, 2014.

[85] X. Zhu, R. J. Castellani, A. Takeda et al., “Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis,” *Mechanisms of Ageing and Development*, vol. 123, no. 1, pp. 39–46, 2001.

[86] A. Ferreira, Q. Lu, L. Orecchio, and K. S. Kosik, “Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar Aβ,” *Molecular and Cellular Neurosciences*, vol. 9, no. 3, pp. 220–234, 1997.

[87] Z. Cai, G. Chen, W. He, M. Xiao, and L. J. Yan, “Activation of MTOR: a culprit of Alzheimer’s disease!,” *Neuropsychiatric Disease and Treatment*, vol. 11, pp. 1015–1030, 2015.

[88] P. Liu, L. Wu, G. Peng et al., “Altered microbiomes distinguish Alzheimer’s disease from amnestic mild cognitive impairment and health in a Chinese cohort,” *Brain, Behavior, and Immunity*, vol. 80, pp. 633–643, 2019.

[89] B. Li, Y. He, J. Ma et al., “Mild cognitive impairment has similar alterations as Alzheimer’s disease in gut microbiota,” *Alzheimer’s & Dementia*, vol. 15, no. 10, pp. 1357–1366, 2019.

[90] C. Wang, Y. Zhao, and Y. Jin, “The emerging PFOS alternative OBS exposure induced gut microbiota dysbiosis and hepatic metabolism disorder in adult zebrafish,” *Journal of Mathematical Analysis and Applications*, vol. 230, p. 108703, 2020.

[91] J. M. Han, S. J. Jeong, M. C. Park et al., “Leucyl-TRNA synthetase is an intracellular leucine sensor for the MTORC1-signaling pathway,” *Cell*, vol. 149, no. 2, pp. 410–424, 2012.

[92] H. Wu, D. Lu, H. Jiang et al., “Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury,” *Journal of Neurotrauma*, vol. 25, no. 2, pp. 130–139, 2008.